Pharmafile Logo
Pharmafocus logo
Advanced Search

schizophrenia

Showing 15 posts of 34 posts found.

schizophrenia_fmri_working_memory

Cambridgeshire and Peterborough NHS Foundation Trust launches mental health clinical trials

February 4, 2019
Sales and Marketing UK, clinical trials, clozapine, mental health, schizophrenia

The Cambridgeshire and Peterborough NHS Foundation Trust’s Windsor Research Unit is offering patients the chance to participate in clinical trials …

News
psm_v46_d168_mesial_view_of_the_human_brain

Commonly used heart and diabetes drugs may improve mental health, study finds

January 10, 2019
Research and Development UCL, bipolar, mental health, research, schizophrenia

Commonly used anti-cholesterol drugs, blood pressure drugs and medicines used for diabetes may improve the mental health of those with …

News
otsuka_web

Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3

August 1, 2018
Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia

It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …

News
astrazeneca_sign_sky

AstraZeneca jettisons schizophrenia drug for $538 million

May 8, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia

AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …

News

Avatar therapy holds potential as adjunct therapy for schizophrenia

November 24, 2017
Medical Communications biotech, drugs, pharma, pharmaceutical, schizophrenia

Experts have developed a new form of therapy for patients living with schizophrenia, by allowing those individuals to speak to …

News
janssen_latest_logo_on_sign_closer

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016
Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …

News
heptares_logo

Heptares announces positive early-stage dementia trial results

February 10, 2016
Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …

News
aristada

FDA approves Alkermes schizophrenia treatment

October 6, 2015
Research and Development Alkermes, Aristada, FDA, schizophrenia

The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …

News
Rexulti (brexpiprazole)

FDA approves Lundbeck and Otsuka’s Rexulti for depression

July 14, 2015
Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia

Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …

News

FDA accepts new schizophrenia drug filing

September 24, 2014
Sales and Marketing FDA, Lundbeck, Otsuka, brexpiprazole, depression, schizophrenia

The FDA is reviewing Otsuka and Lundbeck’s brexpiprazole for the treatment of schizophrenia and as an adjunctive therapy for the …

News
abilify_bms_otsuka

Alkermes schizophrenia drug shines in Phase III

April 8, 2014
Medical Communications, Research and Development, Sales and Marketing Abilify, Alkermes, aripiprazole, schizophrenia

Alkermes’ investigational schizophrenia drug has met its primary endpoint in a pivotal trial, leading the firm to seek regulatory approval …

News
Roche image

Roche schizophrenia drug fails

January 21, 2014
Research and Development, Sales and Marketing Roche, biopertin, schizophrenia

Roche’s investigational schizophrenia drug bitopertin has failed to help patients with the disorder’s negative symptoms when pitted against placebo. Two …

News

GMP certification bodes well for Alexza’s lead product

August 28, 2012
Manufacturing and Production Alexza, FDA, GMP, schizophrenia

US drugmaker Alexza Pharmaceuticals’ manufacturing facility for lead product Adasuve has been given a green light from the Spanish medicine …

News

Janssen’s monthly antipsychotic approved in Europe

March 9, 2011
Sales and Marketing Janssen, Xeplion, antipsychotic, injectible antipsychotic, paliperidone palmitate, schizophrenia

Janssen’s injectable antipsychotic Xeplion has been approved by the European Commission for the treatment of schizophrenia. There is no cure …

News

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025